AstraZeneca sells Atacand rights to Cheplapharm

24th July 2018 Uncategorised 0

AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.

More: AstraZeneca sells Atacand rights to Cheplapharm
Source: News